Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- All-Japan Strategy Necessary for Genomic Research: Dr Nakamura
August 2, 2010
- Taiho: Abraxan for Breast Cancer
August 2, 2010
- Pfizer to Begin PIII Trial for Selara for Chronic Heart Failure
August 2, 2010
- AZ: Pulmicort Inhaler for Asthma in Children
August 2, 2010
- RaQualia Begins PI Trial for APA in the US
August 2, 2010
- Nippon Shinyaku: 4-Time Daily Tramal for Cancer Pain
August 2, 2010
- Victoza Improves SBP without Antihypertensives: Novo Nordisk
August 2, 2010
- Korosho Calls on PMDA to Increase Transparency: Mr Nagatsuma
August 2, 2010
- Edoxaban Superior to Enoxaparin in Preventing VTE after TKR: Daiichi Sankyo
August 2, 2010
- PS Dr Adachi Shows Strong Interest in Gov't-Industry Dialogues
August 2, 2010
- S/GSK1349572 Found Effective in Naive HIV Patients in PIIb: Shionogi
August 2, 2010
- JPA to Present Petition Regarding Generic Substitution for Topical Agents
August 2, 2010
- Carna Bio. Signs License Agreement with JHSF for Anticancer Drug Screening Methods
August 2, 2010
- Korosho to Introduce Japanese Version of ACIP
August 2, 2010
- Survey Conducted by OPA Shows Good Compliance
August 2, 2010
- 29 Drugs Including Forteo, Orencia Approved
August 2, 2010
- Livalo to Be Approved in 16 European Countries
August 2, 2010
- Conduct KRAS Gene Testing before First-Line Treatment for CRC: Dr Yoshino of NCC
August 2, 2010
- Celgene Launches Revlimid, Lenadex for Multiple Myeloma
August 2, 2010
- T-DM1 Applied to FDA for Advanced HER2-Positive Breast Cancer: Roche
August 2, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…